Medical Science Liaison — Neuroscience; Alzheimer’s Disease

At Lilly, the work is demanding because patients are waiting. We unite caring with discovery to help make life better for people around the world, knowing that every decision, every detail, and every day matters. Headquartered in Indianapolis, Indiana, our over 50,000 employees around the globe take on complex challenges to discover and deliver life-changing medicines, strengthen how health is understood and managed, and support the communities we serve.

This is hard, urgent, selfless work—but it’s work worth doing. If you’re driven by purpose and ready to bring your best to work that truly matters for patients, we invite you to join us.

At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, and in Mexico we have been making medicines since 1908. Driven by our enduring values of Integrity, Excellence, and Respect for People
, we put people first — in our labs, in our communities, and in our workplaces.

Neuroscience is one of Lilly’s most enduring scientific commitments, and Alzheimer’s disease is among the fastest-moving fields in medicine — moving from symptomatic management toward biologically confirmed diagnosis, earlier detection, and intervention in the early symptomatic stages of disease. As a Medical Science Liaison (MSL), you will be a credible, field-based scientific partner: translating complex evidence into clinical practice, building trust-based relationships with healthcare experts, and generating the insights that shape Lilly’s medical strategy in México — in a therapeutic area where the diagnostic pathway itself must be strengthened alongside the science.

• Maintain expert command of the evidence across Alzheimer’s disease and the wider neurodegeneration landscape — amyloid and tau biology, fluid and imaging biomarkers, cognitive and functional endpoints, and Lilly’s current and pipeline neuroscience assets, engaging on investigational assets only in a reactive, compliant manner.
• Translate clinical trial data, real-world evidence, HEOR outputs, and updates to diagnostic criteria and clinical guidance (NIA-AA, IWG, AAN, Alzheimer’s Association appropriate-use recommendations, Academia Mexicana de Neurología) into clear, balanced, guideline-aligned scientific narratives.
• Discuss safety and monitoring considerations for this class of therapies — including imaging surveillance requirements and patient risk-stratification — with the balance and rigor the topic demands.
• Respond to unsolicited scientific inquiries with rigorous, non-promotional, evidence-based information.

• Map, prioritize, and build trust-based partnerships with scientific and clinical experts across neurology, cognitive and behavioral neurology, geriatrics, psychiatry, neuroradiology and nuclear medicine, neuropsychology, internal medicine, and primary care — recognizing that Alzheimer’s care depends on a diagnostic and treatment chain rather than on a single prescriber.
• Engage the wider care team whose readiness determines whether evidence reaches patients — neuropsychology, imaging and infusion services, nursing, laboratory, and hospital administration colleagues.
• Deliver high-impact scientific presentations to HCPs and multidisciplinary care teams, and provide scientific support at national and international congresses.
• Engage private and public stakeholders (IMSS, ISSSTE, CCINSHAE — including INNN and INGER — COFEPRIS, CENETEC, CSG, SEDENA, SEMAR, PEMEX) in compliant, non-promotional scientific exchange that supports access decisions grounded in evidence.

• C…